Glucose Regulation in the Body: New Understandings for Management
|
|
- Karen Reynolds
- 5 years ago
- Views:
Transcription
1 Glucose Regulation in the Body: New Understandings for Management Curtis Triplitt, PharmD, CDE Texas Diabetes Institute Assistant Professor, Medicine/Diabetes University of Texas Health Science Center at San Antonio San Antonio, TX 1
2 Faculty Information Presenter Curtis Triplitt, PharmD, CDE Texas Diabetes Institute Assistant Professor, Medicine/Diabetes University of Texas Health Science Center at San Antonio San Antonio, TX Q&A Moderator Jeff D. Prescott, PharmD, RPh Vice President, Clinical and Scientific Affairs American Journal of Managed Care This activity is supported by an educational grant from Bristol-Myers Squibb and AstraZeneca LP. 2
3 Disclosures Curtis Triplitt, PharmD, CDE, has disclosed the following commercial financial relationships: Consultant/Advisory Board: Roche, Takeda Pharmaceuticals Speaker s Bureau: Amylin, Eli Lilly, Pfizer The planning staff from Pharmacy Times Office of Continuing Professional Education have no relevant financial relationships to disclose related to this program. The contents of this webinar may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products. 3
4 Educational Objectives After completion of this activity, participants should be better able to: Examine pathophysiology of diabetes and different mechanisms involved in maintaining glucose balance Explain new understandings in defects of glucose balance and their role in the pathophysiology of diabetes Review the role of different organ systems in maintaining glucose homeostasis 4
5 Pharmacy Accreditation Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This enduring activity is approved for 1 contact hour (0.1 CEU) under the ACPE universal activity number H01-P. This activity is available for CE credit through October 19, Type of Activity: Knowledge 5
6 Glucose Regulation in the Body: New Understandings for Management Curtis Triplitt, PharmD, CDE Texas Diabetes Institute Assistant Professor, Medicine/Diabetes University of Texas Health Science Center at San Antonio San Antonio, TX 6
7 Glucose Regulation in Diabetes 1. How is glucose tightly regulated in normal healthy people? 2. What are the problems that cause glucose regulation to be abnormal in diabetes? 3. How can each of these 8 key abnormalities be addressed in diabetes? 7
8 The Lingo Gluconeogenesis: making glucose Glycogen: stored glucose Glycogenolysis: breaking down stored glucose FFA: free fatty acid Ra: rate of appearance of glucose Rd: rate of disappearance of glucose NGT: normal glucose tolerance IGT: impaired glucose tolerance T2DM: type 2 diabetes mellitus GLP-1: glucagon-like peptide-1 GIP: glucose-dependent insulinotropic polypeptide 8
9 14-6/2000 Pathogenesis of Type 2 Diabetes: Insulin Resistance and -Cell Dysfunction -Cell Dysfunction GLUCOSE INPUTS 1. Gut (meals) Glucose Insulin Resistance Insulin-Sensitive Pathogenesis BLOOD of Type 2 Diabetes: Tissues Insulin Resistance and -Cell Dysfunction -Cell Dysfunction Insulin Resistance Pancreas Liver Muscle Fat 2. Liver (makes and stores glucose) 3. Muscle (storage) VESSEL Pathogenesis of Type 2 Diabetes: In GLUCOSE Resistance and -Cell Dysfunctio -Cell Dysfunction Insulin Resist Pancreas Liver Muscle Fat The rate of movement of glucose out of the circulation is called the glucose disposal rate (Rd) REASN14-6/2000 The rate of glucose appearance into the blood is called Ra which is mainly from the liver or a meal Pancreas Liver Muscle 9
10 Normal, Hyper-, and Hypoglycemic States Ra 100 mg/dl Ra = the rate of appearance of glucose into the blood Rd = the rate of disappearance of glucose from the blood Rd When Ra = Rd = Euglycemic Ra 200 mg/dl Rd Ra 200 mg/dl Ra > Rd; Ra or Rd HYPERGLYCEMIA Rd Ra 50 mg/dl Rd Ra 50 mg/dl Ra < Rd; Ra or Rd HYPOGLYCEMIA Rd 10
11 Glucose Regulation Is Tightly Controlled 11
12 DEFN75-3/99 Impaired Insulin Secretion ETIOLOGY OF T2DM Hyperglycemia HGP Lipolysis Decreased Glucose Uptake Decreased Insulin Secretion Ominous Octet Decreased Incretin Effect Lipolysis Islet α cell Glucagon Secretion Hepatic Glucose Production HYPERGLYCEMIA Neurotransmitter Dysfunction Glucose Reabsorption Decreased Glucose Uptake 12 Adapted from DeFronzo RA. Med Clin N Am. 2004;88(4):
13 DEFN75-3/99 Impaired Insulin Secretion ETIOLOGY OF T2DM Hyperglycemia HGP Lipolysis Decreased Glucose Uptake Decreased Insulin Secretion Ominous Octet Decreased Incretin Effect Lipolysis Islet α cell Glucagon Secretion Hepatic Glucose Production HYPERGLYCEMIA DRUG? Neurotransmitter Dysfunction Glucose Reabsorption Decreased Glucose Uptake 13 Adapted from DeFronzo RA. Med Clin N Am. 2004;88(4):
14 Overflow Hypothesis Adipocytes represent a storage depot for energy (ie, fat). When the capacity of adipocytes to store fat is exceed, there is an overflow of fat to: Muscle Liver Pancreas Fat cell insulin resistance HGP (gluconeogenesis) insulin secretion sick HGP indicates hepatic glucose production. 14
15 Lipotoxicity Insulin Secretion Gluconeogenesis Glucose Oxidation FFA FFA FFA Send discussion questions to FFA indicates free fatty acid. 15
16 Insulin Sensitivity (Clamp Log 10 M) (mg/min kg FFM ) Relationship Between Insulin Sensitivity and Intramyocellular Triglyceride Concentration in Pima Indians With NGT r = P < FFM indicates fat-free mass; NGT, normal glucose tolerance Skeletal Muscle Associated Triglyceride ( mol/g wet weight of tissue) Reprinted with permission from Pan DA, Lillioja S, Kriketos AD, et al. Diabetes. 1997;46(6):
17 Suppression of HGP (mg/m 2 min) Impact of Hepatic Fat Content on Ability to Decrease Hepatic Glucose Production 125 FPI (pm) 100 Baseline Baseline Lo Fat 32±4 Hi Fat 44±3 b a P <.05; b P < With Insulin Low Liver Fat (1.7%) FPI indicates fasting plasma insulin; HGP, hepatic glucose production. a With Insulin High Liver Fat (10.5%) LEAN MEN WITHOUT DIABETES Seppälä-Lindroos A, Vehkavaara S, Häkkinen AM, et al. J Clin Endocrinol Metab. 2002;87(7):
18 % Suppression of EGP by Insulin Liver Fat Content and Suppression of Glucose Production From Liver Insulin Dose (U/day) Liver fat (%) 0 T2DM Patients Treated With Bedtime Insulin + Metformin r = 0.72 P < r = 0.76 P < r = 0.73 P < Liver fat (%) Liver fat (%) Fat mass (kg) EGP indicates endogenous glucose production; T2DM, type 2 diabetes mellitus. 18 Adapted from Ryysy L, Häkkinen AM, Goto T, et al. Diabetes. 2000;49(5):
19 Sick, Dysfunctional Fat Cell ASP & Adipsin MIF FFA IL-6 Leptin PAI-1 ADIPOCYTE Adiponectin TNF Resistin Angiotensinogen ASP indicates acylation-stimulating protein; FFA, free fatty acid; IL-6, interleukin 6; MIF, macrophage migration inhibitory factor; PAI-1, plasminogen activator inhibitor-1; TNF, tumor necrosis factor-alpha. 19
20 DEFN75-3/99 Impaired Insulin Secretion ETIOLOGY OF T2DM Hyperglycemia HGP Lipolysis Decreased Glucose Uptake Decreased Insulin Secretion Islet α cell Ominous Octet Decreased Incretin Effect DRUG? Lipolysis Glucagon Secretion Hepatic Glucose Production HYPERGLYCEMIA Neurotransmitter Dysfunction Glucose Reabsorption Decreased Glucose Uptake 20 Adapted from DeFronzo RA. Med Clin N Am. 2004;88(4):
21 Liver and Kidney Major source of net endogenous glucose production (kidney maybe 10%-15% fasting) Accomplished by gluconeogenesis and glycogenolysis when glucose is low and glycogen synthesis when glucose is high Can oxidize glucose for energy and convert it to fat which can be incorporated into VLDL for transport In T2DM, there is increased gluconeogenesis Send discussion questions to T2DM indicates type 2 diabetes mellitus; VLDL, very low density lipoprotein. 21
22 Regulation of Hepatic Glucose Production DECREASE INCREASE Insulin Hyperglycemia Parasympathetic 0 FFA Cortisol Glucagon Epinephrine Growth Hormone Sympathetic FFA indicates free fatty acid. 22
23 Regulation of Hepatic Glucose Production DECREASE INCREASE Insulin Hyperglycemia Parasympathetic 0 FFA Cortisol Glucagon Epinephrine Growth Hormone Sympathetic FFA indicates free fatty acid. 23
24 Regulation of Hepatic Glucose Production Insulin Hyperglycemia Parasympathetic DECREASE 0 INCREASE FFA Cortisol Glucagon Epinephrine Growth Hormone Sympathetic FFA indicates free fatty acid. 24
25 Direct Versus Indirect Effect of Insulin on Hepatic Glucose Production Direct effect: 60%-70% Indirect effect: 30%-40% FFA (adipocyte) Glucagon (alpha cell) Gluconeogenic precursors Amino acids (muscle) Glycerol (adipocyte) FFA indicates free fatty acid. 25
26 Basal HGP (mg/kg min) Basal Hepatic Glucose Production in T2DM: Relationship With Fasting Plasma Glucose P <.001 Control T2DM r = 0.85, P < Basal HGP (mg/kg min) CONTROL T2DM FPG indicates fasting plasma glucose; HGP, hepatic glucose production; T2DM, type 2 diabetes mellitus FPG (mg/dl) 26 DeFronzo RA, Ferrannini E, Simonson DC. Metabolism. 1989;38(4):
27 Muscle Can convert glucose to glycogen (storage) Can convert glucose to pyruvate through glycolysis; pyruvate is further metabolized to lactate, transaminated to alanine, or channeled into the TCA cycle (energy) In the fasting state, can utilize FFA for fuel and mobilize amino acids by proteolysis for transport to the liver for gluconeogenesis Can break down glycogen (mobilization of stored glucose) FFA indicates free fatty acid; TCA, tricarboxylic acid. 27
28 Insulin Signaling System in Humans Insulin Receptor Plasma Membrane GLUT4 Glucose IRS-1 p85 p110 Akt PI-3-Kinase Protein Synthesis Lipid Synthesis Glycogen Synthesis + Artery GLUT4 indicates glucose transporter type 4; IRS-1, insulin receptor substrate-1; NOS, nitric oxide synthase; PI-3, phosphatidylinositol-3. Adapted from DeFronzo RA. Med Clin N Am. 2004;88(4): Cusi K, Maezono K, Osman A, et al. J Clin Invest. 2000;105(3): ; Miyazaki Y, He H, Mandarino LJ, DeFronzo RA. Diabetes. 2003;52(8):
29 Insulin Receptor Insulin Signaling System in Humans Plasma Membrane IRS-1 p85 p110 Akt GLUT4 PI-3-Kinase Shc + Artery Inflammation Atherosclerosis GLUT4 indicates glucose transporter type 4; IRS-1, insulin receptor substrate-1; MAP, mitogen-activated protein; NOS, nitric oxide synthase; PI- 3, phosphatidylinositol-3. Adapted from DeFronzo RA. Med Clin N Am. 2004;88(4): Cusi K, Maezono K, Osman A, et al. J Clin Invest. 2000;105(3): ; Miyazaki Y, He H, Mandarino LJ, DeFronzo RA. Diabetes. 2003;52(8):
30 DEFN75-3/99 Impaired Insulin Secretion ETIOLOGY OF T2DM Hyperglycemia HGP Lipolysis Decreased Glucose Uptake Decreased Insulin Secretion Ominous Octet Decreased Incretin Effect Lipolysis Islet α cell Glucagon Secretion DRUG? Hepatic Glucose Production HYPERGLYCEMIA Neurotransmitter Dysfunction DRUG? Glucose Reabsorption Decreased Glucose Uptake 30 Adapted from DeFronzo RA. Med Clin N Am. 2004;88(4):
31 Insulin Secretion AIR (µu/ml) Early Insulin Secretion Increases With Decreasing Insulin Action DIA IGT NGT NGT NGT NGT Progressors Insulin Sensitivity M-low (mg/kg EMBS per minute) Non-Progressors AIR indicates acute insulin secretory response; DIA, diabetes; EBMS, estimated metabolic body size; IGT, impaired glucose tolerance; NGT, normal glucose tolerance. Reprinted with permission from Weyer C, Bogardus C, Mott DM, Pratley RE. J Clin Invest. 1999;104(6):
32 FPG (mg/dl) ß-cell Volume (%) Beta Cell Volume Is Related to Fasting Plasma Glucose Levels P < P < NGT IFG T2DM P <.01 P < NGT IFG T2DM FPG indicates fasting plasma glucose; IFG, impaired fasting glucose; NGT, normal glucose tolerance; T2DM, type 2 diabetes mellitus. Adapted from Butler AE, Janson J, Bonner-Weir S, et al. Diabetes. 2003;52(1):
33 INSULIN/ GLUCOSE IR 40 Ability to Release Insulin in Response to a Glucose Load Lean CALCULATED VIA OGTT 10 0 Obese 2-Hour PG (mg/dl) NGT IGT T2DM IGT indicates impaired glucose tolerance; IR, insulin resistance; NGT, normal glucose tolerance; OGTT, oral glucose tolerance test; PG, plasma glucose; T2DM, type 2 diabetes mellitus. 33 Gastaldelli A, Ferrannini E, Miyazaki Y, et al. Beta-cell dysfunction and glucose intolerance: results from the San Antonio metabolism (SAM) study. Diabetologia. 2004;47(1):31-39.
34 Median HBA1c (%) UKPDS: Effect of SU & Metformin Rx on HbA1c 9 Conventional Glibenclamide 8 7 Metformin 6 0 Time (years) HbA1c indicates glycosylated hemoglobin; Rx, prescription; SU, sulfonylurea; UKPDS, United Kingdom Prospective Diabetes Study. UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131): ; UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):
35 Etiology of Beta Cell Failure in T2DM Incretin Effect Age Genetics (TCF7L2) Amyloid (IAPP) Deposition β Cell Failure Insulin Resistance Glucose Toxicity Lipotoxicity FFA FFA indicates free fatty acid; IAPP, islet amyloid polypeptide; TCF7L2, transcription factor 7-like 2; T2DM, type 2 diabetes mellitis. 35
36 Plasma Amylin, pmol/l Amylin Is Co-Secreted With Insulin and Deficient in Diabetes Plasma Insulin, pmol/l Plasma Amylin, pmol/l Meal Meal Meal Meal Amylin Insulin Healthy male adults (n = 6) Without diabetes (n = 12) Insulin-using T2DM (n = 27) T1DM (n = 190) 5 7 AM 12 Noon 5 PM Midnight Time, 24-h Time After Sustacal Meal, min Central satiety; decreases glucagon; slows gastric emptying T1DM indicates type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus. Reprinted with permission from Kruger DF, Gatcomb PM, Owen SK. Diabetes Educ. 1999;25(3):
37 DEFN75-3/99 Impaired Insulin Secretion ETIOLOGY OF T2DM Hyperglycemia HGP Lipolysis Decreased Glucose Uptake Ominous Octet Decreased Insulin Secretion Islet α cell DRUG? Decreased Incretin Effect Lipolysis Glucagon Secretion DRUG? Hepatic Glucose Production HYPERGLYCEMIA Neurotransmitter Dysfunction Glucose Reabsorption Decreased Glucose Uptake 37 Adapted from DeFronzo RA. Med Clin N Am. 2004;88(4):
38 The Incretin Effect Is Reduced in Patients With T2DM In diabetic patients vs. healthy subjects challenged with an oral 50 g glucose load and IV glucose: o Differences between responses to oral and IV glucose were attributed to factors other than glucose itself (incretin effect) o After oral glucose, immunoreactive insulin and connecting peptide responses were delayed in diabetic vs. healthy subjects o After IV glucose, insulin and connecting peptide responses were greater in diabetic patients vs. healthy subjects (as consequence of higher glycemic stimulus) Nauck M, Stöckmann F, Ebert R, Creutzfeldt W. Diabetologia. 1986;29(1):46-52.
39 GLP-1 and GIP Responses in T2DM Postprandial GLP-1 levels are decreased in patients with IGT and T2DM, compared to controls with normal glucose tolerance o Most pronounced GLP-1 decreases seen in T2DM Glucose-dependent insulinotrophic polypeptide (GIP) levels are increased in T2DM, compared to controls with normal glucose tolerance Toft-Nielsen MB, Damholt MB, Madsbad S, et al. J Clin Endocrinol Metab. 2001;86(8): Jones IR, Owens DR, Luzio S, Williams S, Hayes TM. Diabetologia. 1989;32(9):
40 GLP-1 Modulates Numerous Functions in Humans GLP-1: Secreted upon the ingestion of food Exenatide: IV infusion Promotes satiety and reduces appetite α cells: Postprandial glucagon secretion β cells: Enhances glucose-dependent insulin secretion Liver: Glucagon reduces hepatic glucose output (glycogenolysis) Stomach: Helps regulate gastric emptying GLP-1 indicates glucagon-like peptide-1; IV, intravenous. Flint A, Raben A, Astrup A, Holst JJ. J Clin Invest. 1998;101(3): ; Larsson H, Holst JJ, Ahrén B. Acta Physiol Scand. 1997;160(4): ; Nauck MA, Wollschläger D, Werner J, et al. Diabetologia. 1996;39(12): ; Drucker DJ. Diabetes. 1998;47(2):
41 DEFN75-3/99 Impaired Insulin Secretion ETIOLOGY OF T2DM Hyperglycemia HGP Lipolysis Decreased Glucose Uptake Decreased Insulin Secretion Islet α cell Ominous Octet Decreased Incretin Effect DRUG? Lipolysis Glucagon Secretion Hepatic Glucose Production HYPERGLYCEMIA Neurotransmitter Dysfunction Glucose Reabsorption Decreased Glucose Uptake 41 Adapted from DeFronzo RA. Med Clin N Am. 2004;88(4):
42 Renal Handling of Glucose (180 L/day) (900 mg/l) = 162 g/day Glucose SGLT-2 90% S1 10% S3 S G L T 1 Send discussion questions to CEINFO@pharmacytimes.com SGLT indicates sodium glucose cotransporter. NO GLUCOSE 42
43 Fold Increase Normalized Glucose Transporter Levels CPM SGLT-2 Glucose Transporter mrna IN HUMAN RENAL PROXIMAL TUBULAR CELLS 5 SGLT-2 mrna a 6 SGLT-2 PROTEIN AMG UPTAKE a a CON T2DM 0 CON T2DM CON T2DM 0 a P <.05 - P <.01. AMG indicates methyl-α-d-[u14c]-glucopyranoside; CON, control; CPM, counts per minute; mrna, messenger ribonucleic acid; SGLT, sodium glucose cotransporter; T2DM, type 2 diabetes mellitus. 43 Adapted from Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Diabetes. 2005;54(12):
44 Multiple drugs are likely necessary in type 2 diabetes mellitus to address the underlying abnormalities Brain: amylinomimetics, GLP-1 agonists, dopamine agonists Fat: thiazolidinediones (TZDs) Summary Liver and muscle: metformin and TZDs, but HGP can be reduced by mass action through increased insulin (insulin, SU, etc) Glucagon: GLP-1 agonists, DPP-4 inhibitors, amylinomimetics Insulin: insulin, sulfonylureas, meglitinides, DPP-4 inhibitors, and GLP-1 agonists Incretins: GLP-1 agonists, DPP-4 inhibitors, alpha glucosidase inhibitors (?), bile acid sequestrants (?) Renal glucose absorption: SGLT-2 inhibitors (not currently on the market) DPP-4 indicates dipeptidyl peptidase 4; GLP-1, glucagon-like peptide-1; HGP, hepatic glucose production; SGLT, sodium glucose cotransporter; SU, sulfonylurea; TZD, thiazolidinedione. 44
45 Summary Glucose is tightly regulated in our bodies Regulation can be disrupted through many different pathways At least 8 different pathways or abnormalities have been identified in diabetes None of the pathways have been proved to fully correct all of the abnormalities associated with type 2 diabetes mellitus Affecting multiple pathways is likely advantageous 45
46 Glucose Regulation in the Body: New Understandings for Management THANK YOU! For any questions regarding this activity, contact: 46
Achieving Glucose Balance in Type 2 Diabetes Mellitus: Targeted Pharmacotherapy
Achieving Glucose Balance in Type 2 Diabetes Mellitus: Targeted Pharmacotherapy Curtis Triplitt, PharmD, CDE Texas Diabetes Institute Assistant Professor, Medicine/Diabetes University of Texas Health Science
More informationDespite vigorous research aimed at combating type
n reports n Examining the Mechanisms of Glucose Regulation Curtis L. Triplitt, PharmD, CDE Abstract The prevalence of diabetes mellitus (DM) increased by 49% between 1990 and 2000, reaching nearly epidemic
More informationNew and Emerging Therapies for Type 2 DM
Dale Clayton MHSc, MD, FRCPC Dalhousie University/Capital Health April 28, 2011 New and Emerging Therapies for Type 2 DM The science of today, is the technology of tomorrow. Edward Teller American Physicist
More informationEAT TO LIVE: THE ROLE OF THE PANCREAS. Felicia V. Nowak, M.D., Ph.D. Ohio University COM 22 January, 2008
EAT TO LIVE: THE ROLE OF THE PANCREAS Felicia V. Nowak, M.D., Ph.D. Ohio University COM 22 January, 2008 THE ROLE OF THE PANCREAS Exocrine pancreas Endocrine pancreas THE ROLE OF THE PANCREAS EXOCRINE
More informationNormal Fuel Metabolism Five phases of fuel homeostasis have been described A. Phase I is the fed state (0 to 3.9 hours after meal/food consumption),
Normal Fuel Metabolism Five phases of fuel homeostasis have been described A. Phase I is the fed state (0 to 3.9 hours after meal/food consumption), in which blood glucose predominantly originates from
More informationLipids Carbohydrate Protein. Fatty Acids Glycerol. Mono/di-saccarides. Aminoacids. Fat Liver Muscle. Triglycerides Glycogen Protein
Lipids Carbohydrate Protein Fatty Acids Glycerol Mono/di-saccarides Fat Liver Muscle Aminoacids Triglycerides Glycogen Protein Microvascular Macrovascular Diabetes-specific Diabetes-enhanced HbA1c 5.7(6.0)
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationDiabetes: Definition Pathophysiology Treatment Goals. By Scott Magee, MD, FACE
Diabetes: Definition Pathophysiology Treatment Goals By Scott Magee, MD, FACE Disclosures No disclosures to report Definition of Diabetes Mellitus Diabetes Mellitus comprises a group of disorders characterized
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationENERGY FROM INGESTED NUTREINTS MAY BE USED IMMEDIATELY OR STORED
QUIZ/TEST REVIEW NOTES SECTION 1 SHORT TERM METABOLISM [METABOLISM] Learning Objectives: Identify primary energy stores of the body Differentiate the metabolic processes of the fed and fasted states Explain
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationHormonal Regulations Of Glucose Metabolism & DM
Hormonal Regulations Of Glucose Metabolism & DM What Hormones Regulate Metabolism? What Hormones Regulate Metabolism? Insulin Glucagon Thyroid hormones Cortisol Epinephrine Most regulation occurs in order
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationla prise en charge du diabète de
N21 XIII Congrès National de Diabétologie, 29 mai 2011, Alger Intérêt et place des Anti DPP4 dans la prise en charge du diabète de type 2 Nicolas PAQUOT, MD, PhD CHU Sart-Tilman, Université de Liège Belgique
More information28 Regulation of Fasting and Post-
28 Regulation of Fasting and Post- Prandial Glucose Metabolism Keywords: Type 2 Diabetes, endogenous glucose production, splanchnic glucose uptake, gluconeo-genesis, glycogenolysis, glucose effectiveness.
More informationWhat systems are involved in homeostatic regulation (give an example)?
1 UNIVERSITY OF PNG SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY AND MOLECULAR BIOLOGY GLUCOSE HOMEOSTASIS (Diabetes Mellitus Part 1): An Overview
More informationPathogenesis of Diabetes Mellitus
Pathogenesis of Diabetes Mellitus Young-Bum Kim, Ph.D. Associate Professor of Medicine Harvard Medical School Definition of Diabetes Mellitus a group of metabolic diseases characterized by hyperglycemia
More informationDiscussion & Conclusion
Discussion & Conclusion 7. Discussion DPP-4 inhibitors augment the effects of incretin hormones by prolonging their half-life and represent a new therapeutic approach for the treatment of type 2 diabetes
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationChanging Diabetes: The time is now!
Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison
More informationHistory of Investigation
Acini - Pancreatic juice (1º) (2º) Secretions- neuronal and hormonal mechanisms 1) Secretin - bicarbonate rich 2) Cholecystokinin - enzyme rich Islets of Langerhans (contain 4 cell types) Alpha cells (α)-
More informationUNIVERSITY OF PNG SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY AND MOLECULAR BIOLOGY
1 UNIVERSITY OF PNG SCHOOL OF MEDICINE AND HEALTH SCIENCES DIVISION OF BASIC MEDICAL SCIENCES DISCIPLINE OF BIOCHEMISTRY AND MOLECULAR BIOLOGY GLUCOSE HOMEOSTASIS An Overview WHAT IS HOMEOSTASIS? Homeostasis
More informationDiabetes update - Diagnosis and Treatment
Diabetes update - Diagnosis and Treatment Eugene J Barrett, MD,PhD Madge Jones Professor of Medicine Director, University of Virginia Diabetes Center Disclosures - None Case 1 - Screening for Diabetes
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationHelpful Hints for Taking Care of Your Diabetes. Farahnaz Joarder, MD and Don Kain, MA, RD,CDE Harold Schnitzer Diabetes Health Center
Helpful Hints for Taking Care of Your Diabetes Farahnaz Joarder, MD and Don Kain, MA, RD,CDE Harold Schnitzer Diabetes Health Center Objectives How big of a problem is diabetes? What is diabetes? How is
More informationDiabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Diabetes Oral Agents Pharmacology University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Learning Objectives Understand the role of the utilization of free
More informationUnderstanding the Mechanisms to Maintain Glucose
n posttest n Understanding the Mechanisms to Maintain Glucose Homeostasis: A Review for Managed Care Instructions After reading Understanding the Mechanisms to Maintain Glucose Homeostasis: A Review for
More informationPathogenesis of Type 2 Diabetes
9/23/215 Multiple, Complex Pathophysiological Abnmalities in T2DM incretin effect gut carbohydrate delivery & absption pancreatic insulin secretion pancreatic glucagon secretion HYPERGLYCEMIA? Pathogenesis
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationThe enteroinsular axis in the pathogenesis of prediabetes and diabetes in humans
The enteroinsular axis in the pathogenesis of prediabetes and diabetes in humans Young Min Cho, MD, PhD Division of Endocrinology and Metabolism Seoul National University College of Medicine Plasma glucose
More informationDiabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationDIABETES EDUCATION FOR HEALTH CARE SERIES
American Association of Diabetes Educators Provider is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. DIABETES EDUCATION
More information18. PANCREATIC FUNCTION AND METABOLISM. Pancreatic secretions ISLETS OF LANGERHANS. Insulin
18. PANCREATIC FUNCTION AND METABOLISM ISLETS OF LANGERHANS Some pancreatic functions have already been discussed in the digestion section. In this one, the emphasis will be placed on the endocrine function
More informationPancreatic b-cell Dysfunction in Type 2 Diabetes ZIAD KAHWASH, M.D. Insulin resistance: Defects in Insulin Signaling
Plasma insulin (mu/ml) ZIAD KAHWASH, M.D. resistance: Defects in Signaling Increased glucose production Glucose Insufficient glucose disposal X Liver glucagon insulin Pancreas Peripheral tissues (skeletal
More informationObesity, Metabolic Syndrome, and Diabetes: Making the Connections
Obesity, Metabolic Syndrome, and Diabetes: Making the Connections Alka M. Kanaya, M.D. Associate Professor of Medicine & Epi/Biostats University of California, San Francisco February 26, 21 Roadmap 1.
More informationDiabetes 2013: Achieving Goals Through Comprehensive Treatment. Session 2: Individualizing Therapy
Diabetes 2013: Achieving Goals Through Comprehensive Treatment Session 2: Individualizing Therapy Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes. Overview. Prevalence of Overweight in the U.S.
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose
More informationMetabolic Syndrome. DOPE amines COGS 163
Metabolic Syndrome DOPE amines COGS 163 Overview - M etabolic Syndrome - General definition and criteria - Importance of diagnosis - Glucose Homeostasis - Type 2 Diabetes Mellitus - Insulin Resistance
More informationGLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION.
GLUCAGON LIKE PEPTIDE (GLP) 1 AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, WEIGHT CONTROL AND CARDIOVASCULAR PROTECTION. Patricia Garnica MS, ANP-BC, CDE, CDTC Inpatient Diabetes Nurse Practitioner North
More informationDPP-4 inhibitor. The new class drug for Diabetes
DPP-4 inhibitor The new class drug for Diabetes 1 Cause of Death in Korea 1 st ; Neoplasm 2 nd ; Cardiovascular Disease 3 rd ; Cerebrovascular Disease Diabetes 2 Incidence of Fatal or Nonfatal MI During
More informationTreating Type 2 Diabetes with Bariatric Surgery. Goal of Treating T2DM. Remission of T2DM with Bariatric
Treating Type 2 Diabetes with Bariatric Surgery Number (in Millions) of Persons with Diagnosed Diabetes, United States, 198 25 The number of Americans with diabetes increased from 5.6 to 15.8 million Guilherme
More informationIDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and Diabetes Atlas -sixth Edition: IDF 2013
IDF Regions and global projections of the number of people with diabetes (20-79 years), 2013 and 2035 Diabetes Atlas -sixth Edition: IDF 2013 Diabetes Atlas -sixth Edition: IDF 2013 Chronic complications
More informationHormonal regulation of. Physiology Department Medical School, University of Sumatera Utara
Hormonal regulation of nutrient metabolism Physiology Department Medical School, University of Sumatera Utara Homeostasis & Controls Successful compensation Homeostasis reestablished Failure to compensate
More informationAbstract. Effect of sitagliptin on glycemic control in patients with type 2 diabetes. Introduction. Abbas Mahdi Rahmah
Effect of sitagliptin on glycemic control in patients with type 2 diabetes Abbas Mahdi Rahmah Correspondence: Dr. Abbas Mahdi Rahmah Consultant Endocrinologist, FRCP (Edin) Director of Iraqi National Diabetes
More informationA New Therapeutic Strategey for Type II Diabetes: Update 2008
Live, One Hour Webinar A New Therapeutic Strategey for Type II Diabetes: Update 2008 Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy in Grundy, Virginia.
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationUpdate on GLP-1 Past Present Future
Update on GLP-1 p Past Present Future Effects of GLP-1: Glucose Metabolism and Nutritional Balance L-Cells: Glp-1 release Betacellfollowing ingestion Stress Increases satiety reduces appetite Betacell-
More informationEffects of Exercise and Physical Activity on Diabetes Mellitus and Obesity
1 EXERCISE IS MEDICINE: The Science Behind the Movement Effects of Exercise and Physical Activity on Diabetes Mellitus and Obesity Rosa Allyn G. Sy, MD, FPCP, FPSEDM Endocrinology, Diabetes, Metabolism
More informationScope. History. History. Incretins. Incretin-based Therapy and DPP-4 Inhibitors
Plasma Glucose (mg/dl) Plasma Insulin (pmol/l) Incretin-based Therapy and Inhibitors Scope Mechanism of action ผศ.ดร.นพ.ว ระเดช พ ศประเสร ฐ สาขาว ชาโภชนว ทยาคล น ก ภาคว ชาอาย รศาสตร คณะแพทยศาสตร มหาว ทยาล
More informationWeek 3, Lecture 5a. Pathophysiology of Diabetes. Simin Liu, MD, ScD
Week 3, Lecture 5a Pathophysiology of Diabetes Simin Liu, MD, ScD General Model of Peptide Hormone Action Hormone Plasma Membrane Activated Nucleus Cellular Trafficking Enzymes Inhibited Receptor Effector
More informationHot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care
Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Mary Jean Christian, MA, MBA, RD, CDE Diabetes Program Coordinator UC Irvine Health Hot Topics: Diabetes
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More information22 Emerging Therapies for
22 Emerging Therapies for Treatment of Type 2 Diabetes Siddharth N Shah Abstract: The prevalence of Diabetes is progressively increasing world-wide and the growth of the disease in our country is phenomenal.
More informationPre-diabetes. Pharmacological Approaches to Delay Progression to Diabetes
Pre-diabetes Pharmacological Approaches to Delay Progression to Diabetes Overview Definition of Pre-diabetes Risk Factors for Pre-diabetes Clinical practice guidelines for diabetes Management, including
More informationGLP-1. GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4.
GLP-1 GLP-1 is produced by the L-cells of the gut after food intake in two biologically active forms It is rapidly degraded by DPP-4 Food intake éinsulin Gut églucose uptake Pancreas Beta cells Alpha cells
More informationIL METABOLISMO EPATICO DEI CARBOIDRATI IN FISIOLOGIA E PATOLOGIA
UNIGASTRO Il fegato come centrale metabolica e i fattori di danno oltre ai virus epatitici IL METABOLISMO EPATICO DEI CARBOIDRATI IN FISIOLOGIA E PATOLOGIA Dr Elisabetta Bugianesi Divisione di Gastro-Epatologia
More informationUpdate on Diabetes Mellitus
Update on Diabetes Mellitus Treatment: Targeting the Incretin System Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose control Amylin Incretin Hormones New therapies
More informationGLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the
More informationTherapeutic strategy to reduce Glucagon secretion
Clinical focus on glucagon: α-cell as a companion of β-cell Therapeutic strategy to reduce Glucagon secretion Sunghwan Suh Dong-A University Conflict of interest disclosure None Committee of Scientific
More informationThe Emerging Role of the Kidney and SGLT2 Inhibition for Patients with Type 2 Diabetes
Silvio E. Inzucchi, MD The Emerging Role of the Kidney and SGLT2 Inhibition for Patients with Type 2 Diabetes Professor of Medicine Clinical Director Section of Endocrinology Yale University New Haven,
More informationClinical Overview of Combination Therapy with Sitagliptin and Metformin
Clinical Overview of Combination Therapy with Sitagliptin and Metformin 1 Contents Pathophysiology of type 2 diabetes and mechanism of action of sitagliptin Clinical data overview of sitagliptin: Monotherapy
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationNew Treatments for Type 2 diabetes. Nandini Seevaratnam April 2016 Rushcliffe Patient Forum
New Treatments for Type 2 diabetes Nandini Seevaratnam April 2016 Rushcliffe Patient Forum Overview Growing population of Type 2 diabetes Basic science on what goes wrong Current treatments Why there is
More informationGlucose. Glucose. Insulin Action. Introduction to Hormonal Regulation of Fuel Metabolism
Glucose Introduction to Hormonal Regulation of Fuel Metabolism Fasting level 3.5-5 mmol (1 mmol = 18 mg/dl) Postprandial 6-10 mmol Amount of glucose in circulation is dependent on: Absorption from the
More informationDiabetes Education: A Comprehensive Review
Diabetes Education: A Comprehensive Review Module 1: Pathophysiology and Prevention of Diabetes Planning Committee: Michael Boivin, B. Pharm. Johanne Fortier, BSc.Sc, BPh.LPh, CDE Carlene Oleksyn, B.S.P.
More informationDiabetes: Three Core Deficits
Diabetes: Three Core Deficits Fat Cell Dysfunction Impaired Incretin Function Impaired Appetite Suppression Obesity and Insulin Resistance in Muscle and Liver Hyperglycemia Impaired Insulin Secretion Islet
More informationEnrique Caballero, MD Director, Latino Diabetes Initiative Joslin Diabetes Center Harvard Medical School
New Diabetes Treatments Embryonic Stem Cells (ESC) Ectoderm Mesoderm Enrique Caballero, MD Director, Latino Diabetes Initiative Joslin Diabetes Center Harvard Medical School ESC Endoderm Pancreas Islet
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationSubject Index. postprandial glycemia and suppression in serum 51 recommendations 119, 120 supplementation pros and cons 118, 119
Acarbose, diabetes prevention trials 32, 33, 40 42 Accelerator hypothesis accelerators beta cell autoimmunity 140, 141, 147, 150, 151 insulin resistance 140, 142 144, 150 obesity 145 148 diabetes risk
More informationAdipose Tissue as an Endocrine Organ. Abdel Moniem Ibrahim, MD Professor of Physiology Cairo University
Adipose Tissue as an Endocrine Organ Abdel Moniem Ibrahim, MD Professor of Physiology Cairo University Functions of Adipose Tissue Adipose tissue expresses and secretes a variety of bioactive peptides,
More informationWhat to add after metformin: primary care conference 2016
objectives What to add after metformin: primary care conference 216 Dr. Tsang Man Wo Specialist in Endocrinology, Diabetes & Metabolism Medical Director, United Medical Practice. Consultant (P), M+G department,
More informationUpdate on Agents for Type 2 Diabetes
Update on Agents for Type 2 Diabetes This presentation will: Outline the clinical considerations in the selection of pharmacotherapy for type 2 diabetes, including degree of A1C lowering achieved, patient-specific
More informationJulie White, MS Administrative Director Boston University School of Medicine Continuing Medical Education
MENTOR QI Diabetes Performance Improvement Initiative, Getting Patients to Goal in Glycemic Control: Current Data Julie White, MS Administrative Director Boston University School of Medicine Continuing
More informationIncretins: based therapy for type -2 Diabetes mellitus (T2DM)
Int. J. Pharm. Med. Res. 2014; 2(2):38-42 ISSN: 2347-7008 Review article International Journal of Pharmaceutical and Medicinal Research Incretins: based therapy for type -2 Diabetes mellitus (T2DM) Sinha
More information6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE
Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold
More informationType 2 DM in Adolescents: Use of GLP-1 RA. Objectives. Scope of Problem: Obesity. Background. Pathophysiology of T2DM
Type 2 DM in Adolescents: Use of GLP-1 RA Objectives Identify patients in the pediatric population with T2DM that would potentially benefit from the use of GLP-1 RA Discuss changes in glycemic outcomes
More informationIl blocco del cotrasportatore. della terapia antiiperglicemica. Anna Solini
Il blocco del cotrasportatore sodioglucosio come target della terapia antiiperglicemica Anna Solini Dipartimento di Patologia Chirurgica, Medica, Molecolare e dell Area Critica Università di Pisa Grant
More informationThe epidemic continues
Epidemiology!and!Pathophysiology of!type!2!diabetes!and!obesity!! Israel!A.!Hartman,!MD,!FACE Clinical!Instructor!of!Internal!Medicine UT!Southwestern Medical!Center Dallas,!Texas Diabetes in the USA >26
More informationThe endocrine pancreas. The integrated endocrine control of metabolism.
The endocrine pancreas The integrated endocrine control of metabolism. Gabriella Kékesi 62. The endocrine pancreas. Identify the major hormones secreted from the endocrine pancreas (insulin, glucagon,
More information3/22/2017. Type 2 Diabetes Pathophysiology and Pharmacology Review. Accreditation Statement
Type 2 Diabetes Pathophysiology and Pharmacology Review Joshua J. Neumiller, PharmD, CDE, FASCP Vice Chair & Associate Professor, Department of Pharmacotherapy Washington State University Spokane, WA This
More informationDiabetes and Current Therapeutics
Diabetes and Current Therapeutics MacMillan Group Meeting April 4, 2012 Scott Simonovich Definition and World Prevalence Diabetes mellitus Metablic disease in which abnormally high blood glucose levels
More informationDiabetes Mellitus Type 2 Evidence-Based Drivers
This module is supported by an unrestricted educational grant by Aventis Pharmaceuticals Education Center. Copyright 2003 1 Diabetes Mellitus Type 2 Evidence-Based Drivers Driver One: Reducing blood glucose
More informationPharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes
Pharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes Brooke Hudspeth, PharmD, CDE, MLDE Director of Diabetes Prevention, Kroger Pharmacy Adjunct Assistant Professor, University
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,000 116,000 120M Open access books available International authors and editors Downloads Our
More informationAdrenal Hormone Mineralocorticoids Aldosterone
Adrenal gland Adrenal Hormone Mineralocorticoids Aldosterone Cortex 80 % Glucocorticoids Cortisol Sex hormones Androgen Medulla 20% Catecholamines E, NE 1 2 Adrenal cortex hormones Glucocorticoid Mineralocorticoids
More informationCME/CE QUIZ CME/CE QUESTIONS
CME/CE QUIZ CME/CE QUESTIONS Continuing Medical Education Accreditation The University of Cincinnati College of Medicine designates this educational activity for a maximum of two (2) AMA PRA Category 1
More informationFaculty. Concentrated Insulin: Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management. Disclosures. Learning Objectives
Examining the Necessity of Newer Insulins for In-Hospital Diabetes Management Faculty Susan Cornell, PharmD, CDE, FAPhA, FAADE Associate Professor of Pharmacy Practice Associate Director of Experiential
More informationEffects of Exenatide Plus Rosiglitazone on -Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes on Metformin
Clinical Care/Education/Nutrition/Psychosocial Research O R I G I N A L A R T I C L E Effects of Exenatide Plus Rosiglitazone on -Cell Function and Insulin Sensitivity in Subjects With Type 2 Diabetes
More informationOBJECTIVES 4/7/2014. Diabetes Update Overview of the Diabetes Epidemic in the United States. ISHP Annual Spring Meeting
Diabetes Update 2014 ISHP Annual Spring Meeting Hayley Miller MD April 13, 2014 OBJECTIVES Review diabetes guidelines. Understand diabetes management targets. Discuss current therapeutic strategies. Overview
More informationIntact Glucagon-like Peptide-1 Levels are not Decreased in Japanese Patients with Type 2 Diabetes
Or i g i n a l Advance Publication Intact Glucagon-like Peptide-1 Levels are not Decreased in Japanese Patients with Type 2 Diabetes Soushou Lee*, Daisuke Yabe**, Kyoko Nohtomi*, Michiya Takada*, Ryou
More informationDiabetes: What is the scope of the problem?
Diabetes: What is the scope of the problem? Elizabeth R. Seaquist MD Division of Endocrinology and Diabetes Department of Medicine Director, General Clinical Research Center Pennock Family Chair in Diabetes
More informationEffect of macronutrients and mixed meals on incretin hormone secretion and islet cell function
Effect of macronutrients and mixed meals on incretin hormone secretion and islet cell function Background. Following meal ingestion, several hormones are released from the gastrointestinal tract. Some
More informationSESSION 4 12:30pm 1:45pm
SESSION 4 12:30pm 1:45pm Addressing Renal-Mediated Glucose Homeostasis: Diabetes and the Kidney SPEAKER Davida Kruger, MSN, BC-ADM, APRN Presenter Disclosure Information The following relationships exist
More informationInternational Journal of Allied Medical Sciences and Clinical Research (IJAMSCR)
International Journal of Allied Medical Sciences and Clinical Research (IJAMSCR) IJAMSCR Volume 3 Issue 1 Jan-Mar- 2015 www.ijamscr.com Research article Medical research Diabetes mellitus associated mortality:
More informationINSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE
INSULIN IN THE OBESE PATIENT JACQUELINE THOMPSON RN, MAS, CDE SYSTEM DIRECTOR, DIABETES SERVICE LINE SHARP HEALTHCARE OBJECTIVES DESCRIBE INSULIN, INCLUDING WHERE IT COMES FROM AND WHAT IT DOES STATE THAT
More information